Breaking
Cyclone Murasu Threatens Eastern Coast: Four States on High Alert as Storm Intensifies Two Helicopters Collide Near Everest Base Camp Helipad, One Dead Think Twice Before Using Airport USB Ports to Charge Your iPhone—Here’s Why! “Don’t Travel by Air”: Supreme Court’s Blunt Remark on 700% Airfare Hike Sparks Attention New Alzheimer’s Drug Shows Promise, Repairing DNA Damage and Reducing Brain Inflammation Cyclone Murasu Threatens Eastern Coast: Four States on High Alert as Storm Intensifies Two Helicopters Collide Near Everest Base Camp Helipad, One Dead Think Twice Before Using Airport USB Ports to Charge Your iPhone—Here’s Why! “Don’t Travel by Air”: Supreme Court’s Blunt Remark on 700% Airfare Hike Sparks Attention New Alzheimer’s Drug Shows Promise, Repairing DNA Damage and Reducing Brain Inflammation
MinuteBrief logo
Science

New Alzheimer’s Drug Shows Promise, Repairing DNA Damage and Reducing Brain Inflammation

On November 3, 2026, researchers at King's College London announced that an experimental drug originally developed for spinal cord injuries, KCL-286, reduced DNA damage and brain inflammation in Alzheimer’s disease models. Having already passed Phase 1 safety trials in humans, the drug offers a significantly accelerated path toward clinical testing for Alzheimer's patients.

Nilakshi Barman | | 2 min read

New Alzheimer’s Drug Shows Promise, Repairing DNA Damage and Reducing Brain Inflammation
Image courtesy: Shutterstock

In This Story

In Brief

  1. The oral drug KCL-286 activates retinoic acid receptor-beta (RAR-beta) pathways, prompting neuronal repair, reducing DNA breaks, and dampening neuroinflammation.
  2. Mouse studies showed that the compound repairs damaged brain tissue and reduces glial inflammation even after amyloid plaques have already accumulated.
  3. Because the drug has already completed Phase 1 clinical safety and tolerability trials in healthy volunteers, researchers can bypass early toxicity testing to move directly toward proof-of-concept trials in Alzheimer’s patients.
  4. The findings support a broader therapeutic approach that targets multiple root causes of neurodegeneration—such as metabolic dysfunction and DNA damage—rather than focusing solely on clearing single proteins.

Repurposed Spinal Cord Injury Compound KCL-286 Shows Promise as Multi-Target Alzheimer’s Therapy

An experimental drug initially designed to treat spinal cord trauma has emerged as a promising new candidate for tackling Alzheimer’s disease. In preclinical findings published by a team led by King’s College London, the first-in-class small molecule KCL-286 repaired neuronal DNA damage and reduced neuroinflammation, addressing two primary drivers of cognitive decline that operate upstream of traditional protein accumulation.

Activating the Brain's Endogenous Repair Pathways

Unlike existing FDA-approved therapies that focus predominantly on clearing extracellular amyloid-beta plaques or tau tangles, KCL-286 targets retinoic acid receptor-beta (RAR-beta). This receptor acts as a master regulator for nervous system repair, influencing synaptic plasticity, extracellular matrix remodeling, and metabolic regulation.

During laboratory trials on late-stage mouse models exhibiting established plaque pathology, treatment with KCL-286 yielded significant biological repair. Brain tissue analysis revealed reduced levels of markers associated with double-strand DNA breaks and an increased expression of the DNA-repair protein BRCA1. Concurrently, the drug altered the structural behavior of microglia and astrocytes, signaling a reduction in harmful chronic neuroinflammation.

Human Safety Data Accelerates Clinical Timeline

A major hurdle in neurodegenerative drug development is the lengthy timeline required to establish early human safety profiles. However, KCL-286 has already completed Phase 1 safety and tolerability trials involving 109 human volunteers.

While the existing Phase 1 trial data was gathered in healthy individuals and does not yet prove cognitive efficacy in humans, researchers emphasize that the established safety profile provides a crucial head start. The clinical team is now preparing to advance KCL-286 into human efficacy trials, aiming to determine whether repairing genetic damage and mitigating inflammation can preserve memory and daily functionality in early-to-mid stage Alzheimer's patients.



More from Science